CP 55,940Cat. No. 0949 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: (-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol |
Biological Activity
Cannabinoid agonist which is considerably more potent than Δ9-THC in both behavioral tests and receptor binding assays. Displays high and roughly equal affinity for both central and peripheral cannabinoid receptors (Ki = 0.6 - 5.0 and 0.7 - 2.6 nM at CB1 and CB2 respectively; EC50 values are 0.2, 0.3 and 5 nM at CB1, CB2 and GRP55 respectively).Licensing Information
Sold for research purposes under agreement from Pfizer Inc.Certificate of Analysis / Safety Data Sheet
References
Wiley et al (1995) Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34 669. PMID: 7566504.
Griffin et al (1998) Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J.Pharmacol.Exp.Ther. 285 553. PMID: 9580597.
Thomas et al (1998) Comparative receptor binding analyses of cannabinoid agonists and antagonists. J.Pharmacol.Exp.Ther. 285 285. PMID: 9536023.
Avdesh (2011) Corticosteroid dependent and independent effects of a cannabinoid agonist on core temperature, motor activity, and prepulse inhibition of the acoustic startle reflex in Wistar rats. Psychopharmacology Epub ahead of print. PMID: 21947354.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: CP 55,940, supplier, Potent, non-selective, cannabinoids, receptors, agonists, Non-Selective, CP55940, cb2r, cb1r, Pfizer
Quick Order
Find multiple products by catalog number
New Products in this Area
Potent, high affinity CB1 receptor inverse agonist
SR 141716ASelective CB1 receptor antagonist
Tocris Events
Meet your representative
The Role of Cytokines and Signaling in Inflammation
October 15, 2013
Bonn, Germany





